Skip to main content
Premium Trial:

Request an Annual Quote

Citi Research Increases Price Target, EPS Estimates for Agilent

NEW YORK (GenomeWeb News) – Citi Research analyst Amit Bhalla has increased his price target on Agilent Technologies' stock from $43 to $50 and has increased earnings-per-share estimates for the firm.

In a research note published last night Bhalla said that Citi has upped its FY 2013 EPS estimate for Agilent to $3.04 from $3.00 and FY 2014 EPS estimate to $3.40 from $3.29. He also said he believes Agilent will produce organic revenue growth of 4 percent to 5 percent for 2014 and 2015, rather than the 3 percent originally modeled by the bank.

"Combined with the potential for an improved macro environment in 2014 and 2015 … and strength in underlying trends including LC/MS upgrade cycle, diagnostics, and continued growth in smartphones/wireless communication, we believe Agilent remains well positioned and have increased our estimates to reflect this more positive view."

In Monday afternoon trade on the New York Stock Exchange, shares of Agilent were down a fraction of 1 percent at $43.22.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.